Clinical trials: CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Condition CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Funder type Industry (pharma, biotech, devices)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
The main aim of this study is to evaluate the rates of adverse events of special interest (AESIs) (thrombotic events, acute kidney injury [AKI], and hemolytic events) among participants with CIDP initiating GGL compared with…
- Trial name
- NCT05363358
- Where
- United States
- Volunteers
- 6,086 people
- Sponsor
- Takeda
Chronic Inflammatory Demyelinating Polyneuropathy
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)…
- Trial name
- NCT06752356
- Testing
- Immune globulin (human) 10% solution for intravenous administration
- Where
- 5 sites in United States
- Volunteers
- 161 people
- Sponsor
- Kedrion S.p.A.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Objectives: Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive Part B:Long-term safety and tolerability of SAR445088 in CIDP Secondary…
- Trial name
- NCT04658472
- Testing
- SAR445088 (IV), SAR445088 (SC)
- Where
- 32 sites in United States, Canada and 8 more
- Volunteers
- 98 people
- Sponsor
- Bioverativ, a Sanofi company
Polyneuropathy, Inflammatory Demyelinating, Chronic
Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
This study is an observational, ambispective, descriptive, non-interventional study of people with a chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (CIDP) diagnosis in the United States with residual…
- Trial name
- ORBIT-CIDP (NCT06968975)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sanofi
Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome
RWE-based Treatment Patterns and Outcomes in CIDP
To describe the demographics, clinical characteristics, treatment patterns and clinical outcomes of chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), and heredofamilial amyloidosis (hATTR)…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Hereditary Amyloidosis
- Trial name
- NCT05940922
- Testing
- No intervention. Retrospective observation only.
- Where
- United Kingdom
- Volunteers
- 170 people
- Sponsor
- RwHealth
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The purpose of the study is to evaluate clinical efficacy of rozanolixizumab as a treatment for subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- Trial name
- MyCIDPchoice (NCT03861481)
- Testing
- Rozanolixizumab
- Where
- 22 sites in United States, Belgium and 6 more
- Volunteers
- 34 people
- Sponsor
- UCB Biopharma S.P.R.L.
Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
This is a multi-country, prospective safety study of pregnant women exposed to efgartigimod or efgartigimod PH20 SC any time within 25 days prior to conception or any time during pregnancy.
- Trial name
- NCT06299748
- Testing
- Efgartigimod
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 279 people
- Sponsor
- argenx
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
Vitaccess Real CIDP Registry
Vitaccess Real CIDP (VRCIDP) is a patient registry designed to capture longitudinal observational data on chronic inflammatory demyelinating polyneuropathy (CIDP), its treatment, and impact on symptoms, daily activities, and…
- Trial name
- VRCIDP (NCT07006597)
- Volunteers
- 300 people
- Sponsor
- Vitaccess Ltd
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The intent of this study is to demonstrate the efficacy and safety of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in newly or previously diagnosed CIDP subjects.
- Trial name
- ICE (NCT00220740)
- Testing
- Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 32 sites in United States, Argentina and 8 more
- Volunteers
- 117 people
- Sponsor
- Grifols Therapeutics LLC
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Trial name
- emvigorate (NCT06920004)
- Testing
- empasiprubart, IVIg
- Where
- 107 sites in United States, Argentina and 29 more
- Volunteers
- 218 people
- Sponsor
- argenx
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
Primary objective: To assess the efficacy of I10E in improving the disability of patients with CIDP. Secondary objective: To assess the safety of I10E in patients with CIDP.
- Trial name
- PRISM (NCT02293460)
- Testing
- I10E
- Where
- 33 sites in France, Italy and 4 more
- Volunteers
- 44 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP
NewGam (current working title for a new IGIV formulation) is a newly developed human normal immunoglobulin solution ready for intravenous administration (IGIV).
- Trial name
- POINT (NCT01225276)
- Testing
- NewGam 10%
- Volunteers
- 2 people
- Sponsor
- Octapharma
Chronic Inflammatory Demyelinating Polyneuropathy
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
- Trial name
- NCT07032662
- Testing
- Imeroprubart
- Where
- 142 sites in United States, Argentina and 28 more
- Volunteers
- 162 people
- Sponsor
- Immunovant Sciences GmbH
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
- Trial name
- ADHERE+ (NCT04280718)
- Testing
- Efgartigimod PH20 SC
- Where
- 147 sites in United States, Austria and 22 more
- Volunteers
- 229 people
- Sponsor
- argenx